Evidence-based treatment for low-risk basal cell carcinoma

The Lancet Oncology

Volumn 15, Issue 1, 2014, Pages 12-13

  Lear, John T ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID METHYL ESTER; FLUOROURACIL; IMIQUIMOD;

BASAL CELL CARCINOMA; CAUTERIZATION; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CURETTAGE; EVIDENCE BASED MEDICINE; HUMAN; LETTER; LOW RISK POPULATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 84891372556     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70582-5     Document Type: Letter

References (7)

1. Madan V, Lear JT, Szeimies RM Non-melanoma skin cancer. Lancet 2010, 375:673-685.
2. Lear JT Oral hedgehog-pathway inhibitors for basal-cell carcinoma. N Engl J Med 2012, 366:2225-2226.
3. Sinclair R Non-melanoma skin cancer in Australia. Br J Derm 2013, 168:1-2.
4. Telfer NR, Colver GB, Morton CA Guidelines for the management of basal cell carcinoma. Br J Dermatol 2008, 159:35-48. British Association of Dermatologists.
5. Bath-Hexstall F, Ozolins M, Armstrong SJ, et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicenter, non-inferiority, randomized controlled trial. Lancet Oncol 2013, on behalf of the Surgery versus Imiquimod for Nodular and Superficial basal cell carcinoma (SINS) study group, published online Dec 11. http://dx.doi.org/10.1016/S1470-2045(13)70530-8.
6. Arits AH, Mosterd K, Essers BA, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol 2013, 14:647-654.
7. Black N Patient-reported outcome measures in skin cancer. Br J Dermatol 2013, 168:1151.